ArticleCureus2025
Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio as Biomarkers for the Prediction of Activity and Recurrence of Hepatic Echinococcosis: A Retrospective Observational Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydatid disease remains a significant health burden in endemic regions, and recurrence after treatment is a major challenge. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are emerging inflammatory biomarkers, but their role in predicting disease activity and recurrence in hepatic echinococcosis has not been clearly defined.
objectiveThis study aimed to evaluate the diagnostic value of PLR and NLR in determining disease activity and predicting recurrence of hepatic hydatid cysts.
methodsThis retrospective observational cohort study was conducted at Al-Kindi Teaching Hospital, Baghdad, and included 187 patients diagnosed with hepatic hydatid cyst (2016-2020) and 190 age-, sex-, and BMI-matched healthy subjects. Only isolated hepatic cases were included, while patients with concomitant organ involvement, ruptured cysts, comorbid diseases, or incomplete records were excluded. Cysts were classified according to the WHO 2001 classification into active (CE1-CE2), transitional (CE3), and inactive (CE4-CE5) stages. All patients were followed for two years post-treatment with serology and ultrasound every six months to detect recurrence, confirmed by CT when indicated. Complete blood counts were obtained at presentation to calculate platelet-to-lymphocyte (PLR) and neutrophil-to-lymphocyte (NLR) ratios.
resultsPLR and NLR were significantly higher among HC patients compared to healthy individuals (p < 0.001). Both markers increased with disease activity, reaching their highest levels in active cysts (PLR median 246.1 vs. 92.8 in inactive, p < 0.0001). During follow-up, recurrence occurred in 27.2% of patients. Recurrent cases showed lower lymphocyte counts and higher neutrophil, platelet, PLR, and NLR values. On multivariate analysis, PLR emerged as the only independent predictor of recurrence (p = 0.033). ROC analysis demonstrated strong discriminative ability for disease activity (PLR AUC = 0.915; NLR AUC = 0.860) and recurrence (PLR AUC = 0.869; NLR AUC = 0.812).
conclusionPLR and NLR are significantly elevated in hepatic hydatid cysts, especially in active stages. PLR independently predicts recurrence, highlighting the role of systemic inflammation in cyst persistence. Further studies should validate its prognostic value and optimal cutoffs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.